Back to search

Article

Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial

2024-06-11

Abstract excerpt

A phase 1-2, prospective, multicenter, randomized, open-label clinical trial (Code RPCEC00000382, https://rpcec.sld.cu/trials/RPCEC00000382-En/), with parallel groups, involving 1161 participants was designed to assess safety and immunogenicity of two Cuban COVID-19 vaccines (Mambisa and Abdala) in boosting COVID-19 immunity of convalescent adults after receiving one dose of either vaccine. The main safety outcome...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
20aa4363-5cd8-5052-826b-eb8223ff9151
DOI
10.20944/preprints202406.0703.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialDOI 10.20944/preprints202406.0703.v1
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial for Adult Evaluation of the Efficacy and Safety of a Sars-Cov-2 Recombinant Spike Rbd Protein Vaccine (Abdala-3 Study)Semantic proximity
A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study)Semantic proximity
Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)Semantic proximity
Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical TrialSemantic proximity
Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity
Expert Review of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness & Safety During the Omicron-dominant Phase of the PandemicSemantic proximity
Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Semantic proximity
The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary SeriesSemantic proximity
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and diseaseSemantic proximity
Immunogenicity and Safety Assessment of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine (Abdala) in Paediatric Ages 3 to 18 Years Old: A Double-Blinded, Multicentre, Randomised, Phase 1/2 Clinical Trial (ISMAELILLO Study)Semantic proximity
Literature analysis of the efficacy of COVID-19 vaccinationsSemantic proximity
Select a neighboring publication to make it the new centre.